Back

Prevalence and characteristics of the catecholamine induced QT prolongation syndrome

13 April 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Ventricular arrhythmias: epidemiology, prognosis, outcome Epidemiology, Prognosis, Outcome EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Jean Baptiste Gourraud

Institut du Thorax, Nantes (France)

6 More presentations in this session

Presentation thumbnail
Incidence and predictors of major arrhythmic events following acute myocarditis complicated by ventricular arrhythmias: a systematic review and meta-analysis.
Miss S. M'Rabet (Dijon, FR)
Abstract Slides Video
Presentation thumbnail
Predictors and outcomes of electrical storm in patients with sustained ventricular arrhythmias during acute myocardial infarction
Professor C. Guenancia (Dijon, FR)
Abstract Slides Video
Presentation thumbnail
Arrhythmic genotypes and risk of major ventricular arrhythmia in dilated cardiomyopathy: a multicentre japanese cohort
Mr K. Kanaoka (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Phenotypic clustering using cardiac magnetic resonance imaging differentiates genetic background and outcomes in dilated cardiomyopathy.
Doctor E. Goethals (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Pediatric electrical storm: clinical characteristics, management, and outcomes in a multicenter cohort
Doctor F. Alauze (Rennes, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular arrhythmias: epidemiology, prognosis, outcome

The Event

Event poster

EHRA 2026

13 April 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Prevalence and characteristics of the catecholamine induced QT prolongation syndrome
thumbnail
Congress Presentation
ECG red flags in long and short QT syndromes
thumbnail
Congress Presentation
Genotype-specific differences in short QT syndrome include variations in cardiac event timing and ECG features, with potassium channel blockers holding potential as a therapeutic strategy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources